Fundraising Fox
Liquidia Corporation
NASDAQ: LQDAMorrisville, US · Founded 2020 · Delaware corporation · 292 employees on LinkedIn · 4 known investors
Find your way into Liquidia Corporation
Sign up to see every warm intro you have to Liquidia Corporation
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Liquidia Corporation team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Liquidia develops and commercializes inhaled and injectable therapies for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company sells YUTREPIA, an inhaled dry-powder formulation of treprostinil approved by the FDA in May 2025, and shares profits from a generic treprostinil injection marketed by Sandoz, while advancing a pipeline of investigational formulations targeting additional respiratory and vascular diseases.
Founders & leadership
Board
Investors · 4
How we know: Canaan Partners's portfolio page · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$21.7M disclosed across 1 round · 2021
▶$21.7MraisedApr 2021 · 4 investors · BiotechnologyRule 506(b)
- Paul B. ManningDirector
- Joanna HorobinDirector
- Raman SinghDirector
- Stephen BlochDirector
- Roger A. JeffsDirector
- Damian deGoaExecutive Officer, Director
- Arthur KirschDirector
- Michael KasetaExecutive Officer
- David JohnsonDirector
- Katherine Rielly-GauvinDirector
- Offering amount
- $21.7M
- Amount sold
- $21.7M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Liquidia Corporation went on to found or lead other companies.
Related companies · 3
Companies working in the same space as Liquidia Corporation.
Frequently asked questions
- What does Liquidia Corporation do?
- Liquidia develops and commercializes inhaled and injectable therapies for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company sells YUTREPIA, an inhaled dry-powder formulation of treprostinil approved by the FDA in May 2025, and shares profits from a generic treprostinil injection marketed by Sandoz, while advancing a pipeline of investigational formulations targeting additional respiratory and vascular diseases.
- Who are Liquidia Corporation's investors?
- Liquidia Corporation's investors include Canaan Partners, New Enterprise Associates (NEA), Xeraya Capital, PBM Capital.
- How much funding has Liquidia Corporation raised?
- Liquidia Corporation has disclosed $21.7M raised across 1 round.
- Where is Liquidia Corporation headquartered?
- Liquidia Corporation is headquartered in Morrisville, US.